dr. jonasch on using the tumor microenvironment and epigenetics as biomarkers in rcc
Published 5 years ago • 70 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
1:04
dr. jonasch on modulating the tumor microenvironment in rcc
-
0:53
dr. jonasch on the potential of immunotherapy for sarcomatoid rcc
-
1:23
dr. jason luke on utilizing the tumor microenvironment as a biomarker for immunotherapy response
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:10
dr. jonasch on molecular understanding of clear cell rcc
-
0:57
dr. jonasch on sequencing challenges in rcc
-
0:54
dr. jonasch on promise of immuno-oncology agents in rcc
-
7:31
rapidly evolving paradigms for treating advanced rcc
-
0:20
can you kill a tumor cell?
-
0:58
eric jonasch, md, on which non-metastatic renal cell cancer patients should receive adjuvant therapy
-
27:11
what are the next therapies on the horizon for the treatment of kidney cancer? eric jonasch, md
-
0:36
what is epigenetics?
-
1:14
role of cancer epigenetics in tumour classification
-
16:16
molecular tools in diagnosis, prognosis and treatment – impact of microenvironment on cancer behavio
-
0:51
eric jonasch, md, on approaches to consider with metastatic non-clear renal cell carcinoma
-
1:05
research in 60 seconds: birth control & liver tumors
-
4:10
the good, the bad and the epigenetics
-
22:08
frontline treatment for renal cell carcinoma - eric jonasch
-
3:55
the molecular mechanisms of epigenetic therapies: ltrs and tinats